Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their pain treatment, since the pain prevents them from doing various activities, affecting their quality of life. Pain can be present before enlargement of the kidneys, the source of the pain is often unknown and common analgesics are insufficient to manage the pain or cannot be taken due to renal impairment. By further investigating and characterizing the pain phenotype of the ADPKD population, pain management might be improved and alternative therapeutic approaches might be developed. In this clinical study, pain will be assessed in patients with ADPKD using Quantitative Sensory Testing (QST) on the dominant hand and the lower back, together with four questionnaires regarding pain and quality of life. These results will be compared with the somatosensory profile of matched healthy volunteers.
Study Type
OBSERVATIONAL
Enrollment
150
We will perform QST on the dominant hand and lower back.
Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.
UZ Leuven
Leuven, Belgium
RECRUITINGSomatosensory phenotyping of ADPKD using Quantitative Sensory Testing (QST)
The somatosensory phenotype of patients with ADPKD will be evaluated using QST on the dominant hand and lower back. These results will be compared with the somatosensory phenotype of matched healthy volunteers.
Time frame: Interval of ≤ 3 months between screening and study visit
Describing pain in ADPKD using the ADPKD-PDS questionnaire
(Potential) pain in the last 7 days will be assessed using the ADPKD-PDS questionnaire, which contains 20 questions (1-5 Likert scale) in 7 domains: Dull Pain Severity, Sharp Pain Severity, Discomfort Severity, Overall Pain and Discomfort Severity, Dull Pain Interference, Sharp Pain Interference, and Discomfort Interference. Unit of Measure: Total score per domain
Time frame: Interval of ≤ 3 months between screening and study visit
Describing neuropathic pain in ADPKD using the DN4 questionnaire
The DN4 questionnaire will be used to evaluate whether the (potential) pain is neuropathic. The questionnaire consists of 10 yes/no questions, in which a total score of 4/10 or higher is considered indicative of neuropathic pain. Unit of Measure: Total DN4 score (/10)
Time frame: Interval of ≤ 3 months between screening and study visit
Describing quality of life in ADPKD using the ADPKD-IS questionnaire
Quality of life will be assessed using the ADPKD-IS questionnaire, which consists of 18 questions (1-5 Likert scale) in 3 domains (physical, emotional, fatigue) and 4 additional elements (guilt, sleep, size/shape of abdomen, urinary frequency/urgency). Unit of Measure: Total score per domain/element
Time frame: Interval of ≤ 3 months between screening and study visit
Comparing pain between patients with ADPKD and healthy volunteers using the BPI-SF questionnaire
The BPI-SF questionnaire consists of 9 questions, concerning both the intensity and impact of pain on daily functioning in the last 24 hours. This questionnaire will be conducted in patients with ADPKD and healthy volunteers.
Time frame: Interval of ≤ 3 months between screening and study visit
Correlation between QST and questionnaires
A correlation between QST results and results from the questionnaires will be assessed in patients with ADPKD.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in somatosensory phenotype depending on the disease stage of ADPKD
Potential differences in somatosensory phenotype depending on the disease stage of patients with ADPKD (stage 1-5) will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in somatosensory phenotype depending on the sex of patients with ADPKD
Potential differences in the somatosensory phenotype (QST) of female and male patients with ADPKD will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
Differences in pain and quality of life depending on the sex of patients with ADPKD
Potential differences in pain and quality of life, described using questionnaires, of female and male patients with ADPKD will be evaluated using statistical analyses.
Time frame: Interval of ≤ 3 months between screening and study visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.